CTT Pharmaceuticals Holdings, Inc. Announces Uplisting to OTCQB Market Trading
Rhea-AI Summary
CTT Pharmaceutical Holdings (OTCQB:CTTH) has received approval from OTC Markets Group for uplisting its common shares to the OTCQB Market, effective March 10, 2025. The company will continue trading under the symbol 'CTTH'.
The uplisting to OTCQB, a premier marketplace for early-stage pharmaceutical companies developing new technology, is expected to enhance trading liquidity and provide a more streamlined trading experience for U.S. shareholders. Companies listed on OTCQB must maintain current reporting status and undergo annual PCAOB audits.
The company plans to make formal announcements regarding the uplisting on March 10, 2025, followed by a CEO news release to shareholders on March 12, 2025.
Positive
- Uplisting to OTCQB Market approved
- Expected increase in trading liquidity
- Enhanced visibility for U.S. investors
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CTTH declined 14.29%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
TAMPA, FL / ACCESS Newswire / March 5, 2025 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the OTC Markets Group has approved the trading of its common shares on the OTCQB Market. The company's common shares will trade on the OTCQB under the symbol "CTTH" as of the opening of the market on March 10, 2025. Uplisting to the OTCQB should provide CTT with greater liquidity and a more seamless trading experience for U.S. shareholders. The OTCQB is a premier marketplace for Pharmaceutical companies in early stage that are moving towards development of new technology. Companies listed on the OTCQB are current in their reporting and undergo yearly PCAOB Audits. CTT will make a formal announcement on March 10, 2025 announcing the uplisting to the OTCQB investor community. The CEO of CTT Pharma will issue a news release to shareholders on March 12, 2025.
CTT Pharma - 813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire